Join
Live feed
·
PRReleasevia Quantisnow
Mirum Pharmaceuticals Inc. logo
Incyte Corp. logo

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

ByQuantisnow·Wall Street's wire, on your screen.
MIRM· Mirum Pharmaceuticals Inc.INCY· Incyte Corp.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track MIRM (Mirum Pharmaceuticals Inc.), INCY (Incyte Corp.) and more on Quantisnow.

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva | Quantisnow